Publicaciones en colaboración con investigadores/as de Pfizer (United States) (7)

2023

  1. Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial

    Journal of Rheumatology, Vol. 50, Núm. 4, pp. 478-487

2022

  1. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

2021

  1. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

2020

  1. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 20, Núm. 1, pp. 105-114

  2. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810

2019

  1. Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study

    Pituitary, Vol. 22, Núm. 2, pp. 137-145

2014

  1. Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies

    Arthritis and Rheumatology, Vol. 66, Núm. 4, pp. 940-949